Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

INTRODUCTION: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients with advanced ALK-rearranged NSCLC. Here, we assessed the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Daniel S.W., Geater, Sarayut, Yu, Chong-Jen, Tsai, Chun-Ming, Hsia, Te-Chun, Chen, Jun, Lin, Meng-Chih, Lu, You, Sriuranpong, Virote, Yang, Cheng-Ta, Sen, Paramita, Branle, Fabrice, Shi, Michael, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474482/
https://www.ncbi.nlm.nih.gov/pubmed/34589995
http://dx.doi.org/10.1016/j.jtocrr.2020.100131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474482/
https://www.ncbi.nlm.nih.gov/pubmed/34589995
http://dx.doi.org/10.1016/j.jtocrr.2020.100131

Ejemplares similares